These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1234 related items for PubMed ID: 17315165

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC.
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
    Lee HM, Solan MJ, Lupinacci P, Gomella LG, Valicenti RK.
    Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
    [Abstract] [Full Text] [Related]

  • 5. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H.
    BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
    Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML.
    J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
    [Abstract] [Full Text] [Related]

  • 8. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [Abstract] [Full Text] [Related]

  • 9. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
    Bastian PJ, Palapattu GS, Yegnasubramanian S, Lin X, Rogers CG, Mangold LA, Trock B, Eisenberger M, Partin AW, Nelson WG.
    Clin Cancer Res; 2007 Sep 15; 13(18 Pt 1):5361-7. PubMed ID: 17875764
    [Abstract] [Full Text] [Related]

  • 10. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, Koch MO.
    J Urol; 2005 Dec 15; 174(6):2181-5. PubMed ID: 16280760
    [Abstract] [Full Text] [Related]

  • 11. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML.
    J Urol; 2005 Apr 15; 173(4):1121-5. PubMed ID: 15758719
    [Abstract] [Full Text] [Related]

  • 12. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D, Goppelt M, Dorn R, Wawroschek F, Harzmann R.
    BJU Int; 2006 Jun 15; 97(6):1173-8. PubMed ID: 16686707
    [Abstract] [Full Text] [Related]

  • 13. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
    Carver BS, Bianco FJ, Scardino PT, Eastham JA.
    J Urol; 2006 Aug 15; 176(2):564-8. PubMed ID: 16813890
    [Abstract] [Full Text] [Related]

  • 14. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
    Gonzalez CM, Roehl KA, Antenor JV, Blunt LW, Han M, Catalona WJ.
    Urology; 2004 Oct 15; 64(4):723-8. PubMed ID: 15491709
    [Abstract] [Full Text] [Related]

  • 15. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience.
    Xylinas E, Drouin SJ, Comperat E, Vaessen C, Renard-Penna R, Misrai V, Bitker MO, Chartier-Kastler E, Richard F, Cussenot O, Roupret M.
    BJU Int; 2009 May 15; 103(9):1173-8; discussion 1178. PubMed ID: 19040530
    [Abstract] [Full Text] [Related]

  • 16. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
    Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H.
    J Urol; 2000 Jul 15; 164(1):101-5. PubMed ID: 10840432
    [Abstract] [Full Text] [Related]

  • 17. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.
    Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW.
    J Clin Oncol; 2007 May 01; 25(13):1765-71. PubMed ID: 17470867
    [Abstract] [Full Text] [Related]

  • 18. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML.
    J Urol; 2007 Sep 01; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [Abstract] [Full Text] [Related]

  • 19. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
    Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H.
    J Urol; 2003 Nov 01; 170(5):1872-6. PubMed ID: 14532796
    [Abstract] [Full Text] [Related]

  • 20. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK, Levy LB, Cheung R, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):456-62. PubMed ID: 15927415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.